Oppenheimer Downgrades Aerovate(AVTE.US) to Hold Rating, Cuts Target Price to $3
Oppenheimer analyst Andreas Argyrides downgrades $Aerovate(AVTE.US)$ to a hold rating, and adjusts the target price from $41 to $3.According to TipRanks data, the analyst has a success rate of 44.7%
Analysts Conflicted on These Healthcare Names: Oric Pharmaceuticals (ORIC), Aerovate Therapeutics (AVTE) and McKesson (MCK)
Aerovate | 10-Q: Q2 2024 Earnings Report
Aerovate Therapeutics Shares Are Trading Higher After the Company Announced It Is Exploring Strategic Alternatives.
Aerovate Therapeutics To Explore Strategic Alternatives Which May Include But Are Not Limited To, An Acquisition, Merger, Reverse Merger, Business Combination, Liquidation Or Other Transaction
Express News | Aerovate Therapeutics - Wedbush Pacgrow Engaged as Exclusive Advisor